The story of Viagra, and its developer copyright, presents a complex case study for investors. Originally a blockbuster drug, producing billions in sales , its intellectual property lapse created a deluge of generic competition , significantly diminishing its market share . While specific firms may seek to capitalize on similar conditions , the pre